Streetwise Biotech / Pharmaceuticals Articles



NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation
Source: Streetwise Reports  (1/16/20)
Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. More >


Biotech Announces Deal with Bayer on Non-Hormonal Contraception
Source: Streetwise Reports  (1/15/20)
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. More >


Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Source: Streetwise Reports  (1/13/20)
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. More >


Life Sciences Firm Upgrades to OTCQB Venture Market
Source: Streetwise Reports  (1/10/20)
This is a significant achievement of this developing company. More >


Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study
Source: Streetwise Reports  (1/10/20)
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. More >


Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results
Source: Streetwise Reports  (1/9/20)
Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020. More >


Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020
Source: Streetwise Reports  (1/8/20)
The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. More >


Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study
Source: Streetwise Reports  (1/8/20)
Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. More >


Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial
Source: Streetwise Reports  (1/7/20)
Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria. More >


Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan
Source: Streetwise Reports  (1/6/20)
aTyr Pharma's shares traded 45% higher today after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan. More >


Biopharma's Migraine Phase 3 Trial Results 'Robust,' 'Impressive'
Source: Streetwise Reports  (1/3/20)
These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. More >


Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder
Source: Streetwise Reports  (1/3/20)
The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. More >


Biopharma Releases Topline Results from Psoriasis Trial
Source: Streetwise Reports  (1/3/20)
The company, however, will continue to advance the same therapeutic in two other diseases. More >


Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise
Source: Streetwise Reports  (1/3/20)
Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity financing from BeiGene and two other investment groups. More >


Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%
Source: Streetwise Reports  (1/2/20)
Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. More >


Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment
Source: Streetwise Reports  (12/30/19)
Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). More >


Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial
Source: Streetwise Reports  (12/27/19)
Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results in Q1/20. More >


Biopharma Continues 'Positive Push Forward in Breast Cancer'
Source: Streetwise Reports  (12/27/19)
The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report. More >


Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'
Source: Streetwise Reports  (12/23/19)
The key business and investment points are presented in a ROTH Capital Partners report. More >


Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug
Source: Streetwise Reports  (12/23/19)
Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTAŽ (lumateperone) drug for the treatment of schizophrenia in adults. More >


NewLink Genetics Shares Shoot Higher after FDA Ebola Vaccine Approval
Source: Streetwise Reports  (12/20/19)
Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. The company's shares set a new 52-week high price in mid-morning trading. More >


Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax
Source: Streetwise Reports  (12/19/19)
Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. More >


Agreement Sets Stage to Secure Chinese Approval of Non-Antibiotic Livestock Feed Supplement
Source: Streetwise Reports  (12/18/19)
The requirements include, among others, trials of the company's livestock feed additive. More >


Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease
Source: Streetwise Reports  (12/18/19)
Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 million over three years. More >


Biopharma to Test Immunity Activator in Advanced Solid Cancers
Source: Streetwise Reports  (12/17/19)
The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. More >


Showing Results: 1 to 25 of 1055 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe